Virus-like particles as particulate vaccines

Current HIV Research

Volumn 8, Issue 4, 2010, Pages 299-309

  Buonaguro, Luigi ^a   Tornesello, Maria L ^a   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adaptive immunity; Antigen presenting cells; Hiv; Innate immunity; Vaccine; Virus like particles

Indexed keywords

BLUETONG VIRUS VACCINE; CHIMERIC PROTEIN; EBOLA VACCINE; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GREEN FLUORESCENT PROTEIN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS E VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MARBURG VIRUS VACCINE; MEASLES VACCINE; NOROVIRUS VACCINE; POLIOMYELITIS VACCINE; PROTEIN E6; PROTEIN E7; RECOMBINANT VACCINE; REV PROTEIN; ROTAVIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIROSOME VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS LIKE AGENT VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONJUGATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS LIKE AGENT;

HUMANS; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIRUSES;

EID: 77953531894     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791208659     Document Type: Article

References (186)

1. Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res 2009; 84(2): 119-30.
2. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 1993; 196(1): 199-208.
3. Georgescu MM, Balanant J, Macadam A, et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 1997; 71(10): 7758-68.
4. Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine- associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 257(10): 1335-40.
5. Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 1995; 142(2): 109-40.
6. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202(12): 1075-80.
7. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89(4): 422-34.
8. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol 1997; 15: 235-70.
9. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262(5138): 1448-51.
10. Storni T, Ruedl C, Renner WA, Bachmann MF. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol 2003; 171(2): 795-801.
11. Prlic M, Hernandez-Hoyos G, Bevan MJ. Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J Exp Med 2006; 203(9): 2135-43.
12. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172(3): 1777-85.
13. Skountzou I, Quan FS, Gangadhara S, et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulatingfactororCD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 2007; 81(3): 1083-94.
14. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008; 82(23): 11813-23.
15. gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59: 103-12.
16. Delchambre M, Gheysen D, Thines D, et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 1989; 8(9): 2653-60.
17. Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N, Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol 1986; 59: 176-80.
18. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus- like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89: 12180-4.
19. Takamura S, Niikura M, Li TC, et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 2004; 11(7): 628-35.
20. Malboeuf CM, Simon DA, Lee YE, et al. Human papillomavirus- like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 2007; 25(17): 3270-6.
21. Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998; 26(5): 1317-23.
22. Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009; 8(10): 1379-98.
23. Xu YF, Zhang YQ, Xu XM, Song GX. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol 2006; 151(11): 2133-48.
24. Blumberg BS, Alter HJ, VISNICH S. A NEW ANTIGEN IN LEUKEMIA SERA. JAMA 1965; 191: 541-6.
25. Brady JN, Consigli RA. Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein. J Virol 1978; 27(2): 436-42.
26. Fernandez-San MA, Ortigosa SM, Hervas-Stubbs S, et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self- assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 2008; 6(5): 427-41.
27. Maclean J, Koekemoer M, Olivier AJ, et al. Optimization of human papillomavirus type 16(HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007; 88(Pt 5): 1460-9.
28. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185(1): 251-7.
29. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus- like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89(24): 12180-4.
30. Sasagawa T, Pushko P, Steers G, et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995; 206(1): 126-35.
31. Lenzi P, Scotti N, Alagna F, et al. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res 2008; 17(6): 1091-102.
32. Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18(11-12): 1051-8.
33. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV- 16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73(11): 9063-71.
34. Brown DR, Bryan JT, Schroeder JM, et al. Neutralization of human papillomavirus type 11(HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184(9): 1183-6.
35. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92(25): 11553-7.
36. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
37. Evans TG, Bonnez W, Rose RC, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183(10): 1485-93.
38. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93(4): 284-92.
39. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369(9580): 2161-70.
40. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367(9518): 1247-55.
41. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000; 270(2): 254-7.
42. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002; 76(19): 9798-805.
43. Gambhira R, Karanam B, Jagu S, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007; 81(24): 13927-31.
44. Gambhira R, Jagu S, Karanam B, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007; 81(21): 11585-92.
45. Pastrana DV, Gambhira R, Buck CB, et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005; 337(2): 365-72.
46. Varsani A, Williamson AL, de VD, Becker I, Christensen ND, Rybicki EP. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 2003; 77(15): 8386-93.
47. Kawana K, Yasugi T, Kanda T, et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 2003; 21(27-30): 4256-60.
48. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67(12): 6929-36.
49. Slupetzky K, Gambhira R, Culp TD, et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007; 25(11): 2001-10.
50. Lopez de Turiso JA, Cortes E, Martinez C, et al. Recombinant vaccine for canine parvovirus in dogs. J Virol 1992; 66(5): 2748- 53.
51. Martinez C, Dalsgaard K, Lopez de Turiso JA, Cortes E, Vela C, Casal JI. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 1992; 10(10): 684-90.
52. Maranga L, Rueda P, Antonis AF, et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 2002; 59(1): 45-50.
53. Jiang X, Wang M, Graham DY, Estes MK. Expression, self- assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66(11): 6527-32.
54. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998; 72(2): 1345-53.
55. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosa (fecal and vaginal) immune responses. J Virol 2001; 75: 9713-22.
56. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999; 117(1): 40-8.
57. Li TC, Yamakawa Y, Suzuki K, et al. Expression and self- assembly of empty virus-like particles of hepatitis E virus. J Virol 1997; 71: 7207-13.
58. Li T, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001; 19(25-26): 3476-84.
59. Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004; 22(3-4): 370-7.
60. Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus- like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 1993; 192(2): 512-24.
61. Kibenge FS, Qian B, Nagy E, Cleghorn JR, Wadowska D. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can J Vet Res 1999; 63(1): 49-55.
62. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol 1990; 64(12): 5695- 700.
63. French TJ, Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol 1990; 64(4): 1530-6.
64. Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res 1993; 21(5): 1219-23.
65. Roy P, Bishop DH, LeBlois H, Erasmus BJ. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 1994; 12(9): 805-11.
66. Sabara M, Parker M, Aha P, et al. Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins. J Virol 1991; 65(12): 6994-7.
67. Madore HP, Estes MK, Zarley CD, et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 1999; 17(19): 2461-71.
68. Jiang B, Estes MK, Barone C, et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999; 17(7-8): 1005-13.
69. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6- virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003; 21(25-26): 3885-900.
70. Parez N, Fourgeux C, Mohamed A, et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 2006; 80(4): 1752-61.
71. Agnello D, Herve CA, Lavaux A, et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol 2006; 80(8): 3823-32.
72. Istrate C, Hinkula J, Charpilienne A, et al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 2008; 26(35): 4594-601.
73. Ciarlet M, Crawford SE, Barone C, et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 1998; 72: 9233-46.
74. Fernandez FM, Conner ME, Hodgins DC, et al. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines. Vaccine 1998; 16(5): 507-16.
75. Betenbaugh M, Yu M, Kuehl K, et al. Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res 1995; 38(2-3): 111-24.
76. Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 1971; 218(11): 1665-70.
77. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307(5947): 178-80.
78. Wampler DE, Lehman ED, Boger J, McAleer WJ, Scolnick EM. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc Natl Acad Sci USA 1985; 82(20): 6830-4.
79. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004; 72(11): 6519-27.
80. Stahl SJ, Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc Natl Acad Sci USA 1989; 86(16): 6283-7.
81. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001; 44(2-3): 98-114.
82. Mihailova M, Boos M, Petrovskis I, et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 2006; 24(20): 4369-77.
83. Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P. Melanoma vaccine candidates from chimeric hepatitis B core virus- like particles carrying a tumor-associated MAGE-3 epitope. Biotechnol J 2008; 3(11): 1429-36.
84. Geldmacher A, Skrastina D, Borisova G, et al. A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies. Vaccine 2005; 23(30): 3973-83.
85. Walker A, Skamel C, Vorreiter J, Nassal M. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. J Biol Chem 2008; 283(48): 33508-15.
86. Nassal M, Skamel C, Vogel M, et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int J Med Microbiol 2008; 298(1-2): 135-42.
87. Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 1995; 214: 50-8.
88. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72: 3827-36.
89. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001; 75(13): 6154-65.
90. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009; 143(2): 140-6.
91. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3(1): e1501.
92. Crevar CJ, Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 2008; 5: 131.
93. Elmowalid GA, Qiao M, Jeong SH, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007; 104(20): 8427-32.
94. Kang SM, Yoo DG, Lipatov AS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009; 4(3): e4667.
95. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34(2): 417-23.
96. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003; 100(11): 6753-8.
97. Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 2004; 576(1-2): 174-8.
98. Ho Y, Lin PH, Liu CY, Lee SP, Chao YC. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 2004; 318(4): 833-8.
99. Campbell S, Rein A. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol 1999; 73: 2270-9.
100. Campbell S, Vogt VM. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol 1995; 69: 6487-97.
101. Buonaguro L, Buonaguro FM, Tornesello ML, et al. High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Research 2001; 49: 35-47.
102. Niedrig M, Gelderblom HR, Pauli G, et al. Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J Gen Virol 1994; 75: 1469-74.
103. Mammano F, Ohagen A, Hoglund S, Gottlinger HG. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J Virol 1994; 68: 4927-36.
104. Halsey RJ, Tanzer FL, Meyers A, et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res 2008; 133(2): 259-68.
105. gag retrovirus-like particles. Virology 1994; 200: 162-75.
106. Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996; 220: 128-40.
107. Tobin GJ, Li GH, Fong SE, Nagashima K, Gonda MA. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit gag- and SU-specific murine cytotoxic T-lymphocyte activities. Virology 1997; 236: 307-15.
108. Haffar OK, Garrigues J, Travis BM, Moran PA, Zarling JM, Hu SL. Human immunodeficiency virus-like, nonreplicating particles assemble in a recombinant vaccinia virus expression system. J Virol 1990; 64: 2653-9.
109. Vzorov AN, Bukrinsky MI, Grigoriev VB, Tentsov YY, Bukrinskaya AG. Highly immunogenic human immunodeficiency viruslike particles are produced by recombinant vaccinia virus- infected cells. AIDS Res Hum Retroviruses 1991; 7: 29-36.
110. Sakuragi S, Goto T, Sano K, Morikawa Y. HIV type 1 Gag virus- like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 2002; 99: 7956-61.
111. Tsunetsugu-Yokota Y, Morikawa Y, Isogai M, et al. Yeast-derived human immunodeficiency virus type 1 p55gag Virus-Like Particles activate dendritic cells (DCs) and induce perforin expression in gag-specific CD8+ T cells by cross-presentation of DCs. J Virol 2003; 77: 10250-9.
112. Rovinski B, Haynes JR, Cao SX, et al. Expression and characterizationofgeneticallyengineeredhuman immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross- protective AIDS vaccine. J Virol 1992; 66: 4003-12.
113. Scotti N, Alagna F, Ferraiolo E, et al. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta 2009; 229(5): 1109-22.
114. Meyers A, Chakauya E, Shephard E, et al. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol 2008; 8: 53.
115. Hammonds J, Chen X, Zhang X, Lee F, Spearman P. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007; 25(47): 8036-48.
116. Griffiths JC, Harris SJ, Layton GT, et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag: V3 fusion. J Virol 1993; 67: 3191-8.
117. Tobin GJ, Nagashima K, Gonda MA. Use of the particle-forming properties of the HIV gag precursor for packaging additional epitopes into pseudovirions produced in the baculovirus-insect cell expression system. Intervirology 1996; 39: 40-8.
118. Yao Q, Kuhlmann FM, Eller R, Compans RW, Chen C. Production and characterization of simian--human immunodeficiency virus- like particles. AIDS Res Hum Retroviruses 2000; 16: 227-36.
119. Zanotto C, Paganini M, Elli V, et al. Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses. Vaccine 2005; 23: 4745-53.
120. Deml L, Kratochwil G, Osterrieder N, Knuchel R, Wolf H, Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997; 235: 10-25.
121. Hammonds J, Chen X, Fouts T, Devico A, Montefiori D, Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol 2005; 79(23): 14804-14.
122. Crooks ET, Moore PL, Franti M, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007; 366(2): 245-62.
123. Wang BZ, Liu W, Kang SM, et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles 1. J Virol 2007; 81(20): 10869-78.
124. Buonaguro L, Racioppi L, Tornesello ML, et al. Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Research 2002; 54: 189-201.
125. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005; 79: 7059-67.
126. Buonaguro L, Devito C, Tornesello ML, et al. DNA-VLP prime- boost intra-nasal immunization induces cellular and humoral anti- HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007; 25(32): 5968-77.
127. McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007; 358(2): 334-46.
128. Guerbois M, Moris A, Combredet C, et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009; 388(1): 191-203.
129. Quan FS, Sailaja G, Skountzou I, et al. Immunogenicity of virus- like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 2007; 25(19): 3841-50.
130. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285-9.
131. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV- infected individuals. Nature 2009; 458(7238): 636-40.
132. Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 1998; 50: 141-82.
133. Koletzki D, Lundkvist A, Sjolander KB, et al. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology 2000; 276(2): 364-75.
134. Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001; 75(5): 2130-41.
135. Woo WP, Doan T, Herd KA, Netter HJ, Tindle RW. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol 2006; 80(8): 3975-84.
136. De FM, Martens W, Smet A, et al. Universal influenza A M2e- HBc vaccine protects against disease even in the presence of pre- existing anti-HBc antibodies. Vaccine 2008; 26(51): 6503-7.
137. Dale CJ, Liu XS, De Rose R, et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology 2002; 301: 176-87.
138. Hinton HJ, Jegerlehner A, Bachmann MF. Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr Top Microbiol Immunol 2008; 319: 1-15.
139. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 2004; 82(5): 506-16.
140. Buonaguro L, Tornesello ML, Tagliamonte M, et al. Baculovirus- derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006; 80: 9134-43.
141. Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM. Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)- Infected Subjects, as Activated by HIV Virus-Like Particles. J Virol 2009; 83(1): 304-13.
142. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross- presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003; 63: 3478-82.
143. Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clinical Immunology 2003; 106: 231-7.
144. Moron VG, Rueda P, Sedlik C, Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 2003; 171: 2242-50.
145. Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007; 362(2): 331-41.
146. Paliard X, Liu Y, Wagner R, Wolf H, Baenzinger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag- specific CD8+ cytotoxic T cells after administration of a virus- like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000; 16: 273-82.
147. Schirmbeck R, Bohm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996; 39(1-2): 111-9.
148. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38(5): 1404-13.
149. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108(3): 241-7.
150. Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 2005; 79(2): 717-24.
151. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross- presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002; 32(3): 818-25.
152. Bachmann MF, Lutz MB, Layton GT, et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 1996; 26(11): 2595-600.
153. Aricò E, Wang E, Tornesello ML, et al. Immature monocyte derived dendritic cells gene expression profile in response to Virus- Like Particles stimulation. J Transl Med 2005; 3: 45.
154. Buonaguro L, Monaco A, Arico E, et al. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bionformatics 2008; 9(Suppl. 2): S5.
155. Monaco A, Marincola FM, Sabatino M, et al. Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett 2009; 583(18): 3004-8.
156. Frank I, Piatak M, Jr., Stoessel H, et al. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J Virol 2002; 76(6): 2936-51.
157. Bosio CM, Moore BD, Warfield KL, et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004; 326(2): 280-7.
158. Yang R, Martinez Murillo F, Cui H, et al. Papillomavirus-Like Particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 2004; 78: 11152-60.
159. Freer G, Matteucci D. Influence of dendritic cells on viral pathogenicity. PLoS Pathog 2009; 5(7): e1000384.
160. Sevilla N, McGavern DB, Teng C, Kunz S, Oldstone MB. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J Clin Invest 2004; 113(5): 737-45.
161. Hodges A, Sharrocks K, Edelmann M, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007; 8(6): 569-77.
162. Gonzalez PA, Prado CE, Leiva ED, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA 2008; 105(39): 14999-5004.
163. Saito K, it-Goughoulte M, Truscott SM, et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 2008; 82(7): 3320-8.
164. Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol Rev 2007; 220: 214-24.
165. Storni T, Lechner F, Erdmann I, et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002; 168(6): 2880-6.
166. Schwarz K, Storni T, Manolova V, et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 2003; 33(6): 1465-70.
167. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007; 6(4): 223-35.
168. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci USA 2001; 98(20): 11539-44.
169. Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity. Vaccine 1992; 10(7): 439-42.
170. Shouval D, Ilan Y, Adler R, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994; 12(15): 1453-9.
171. Madalinski K, Sylvan SP, Hellstrom U, Mikolajewicz J, Zembrzuska-Sadkowska E, Piontek E. Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine 2001; 20(1-2): 92-7.
172. Purcell RH, Nguyen H, Shapiro M, et al. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 2003; 21(19-20): 2607-15.
173. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18(1): 244-51.
174. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005; 23(50): 5751-9.
175. gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T- cells and neutralizing antibodies. Virology 1997; 235: 26-39.
176. Buonaguro L, Tornesello ML, Buonaguro FM. Virus-like particles (VLPs) as anti-viral vaccines: an effective approach for a HIV-1 vaccine strategy. ASHI Quarterly 2005; 2nd Quarter: 10-3.
177. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100(26): 15889-94.
178. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23(23): 3033-42.
179. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(Suppl 2): S430-S437.
180. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16- specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23(2): 172-81.
181. Weber J, Cheinsong-Popov R, Callow D, et al. Immunogenicity of the yeast recombinant p17/p24: Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995; 13(9): 831-4.
182. Gilbert SC, Plebanski M, Harris SJ, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997; 15(12): 1280-4.
183. Niikura M, Takamura S, Kim G, et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002; 293: 273-80.
184. Billaud JN, Peterson D, Barr M, et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol 2005; 79(21): 13656-66.
185. Eckhart L, Raffelsberger W, Ferko B, et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol 1996; 77(Pt 9): 2001-8.
186. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000; 273(2): 374-82.